1. Tamura Y, Tamura Y , Taniguchi H, Imanaka-Yoshida K. Acute Myocarditis After Discontinuation of Immune Checkpoint Inhibitor Therapy. Circ J. 2023 Jan 25;87(2):376. doi:10.1253/circj.CJ-22-0613.
2. Furukawa A, Tamura Y, Taniguchi H, Ka wamura A, Nagase S, Hayashi A, Tada Y, Sase K, Hatake K: Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol. 2023 Jan;81(1):63-67. doi: 10.1016/j.jjcc.2022.07.009.
3. Tamura Y, Tamura Y, Takemura R, Yamada K, Taniguchi H, Iwasawa J, Yada H, Kawamura A. Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy. JACC. 2022 Dec, 4 (5) 673–685
4. Tamura Y, Tamura Y, Yamada K, Taniguchi H, Iwasawa J, Yada H, Kawamura A: Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy. Heart Vessels. 2022 Nov;37(11):1859-1865. doi: 10.1007/s00380-022-02103-1.
5. Yamada K, Tamura Y, Taniguchi H, Furukawa A, Iwasawa J, Yada H, Kawamura A, Tamura Y: Usefulness of Global Longitudinal Strain-Guided Management in Preventing Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor-Induced Myocardial Damage. Circ Rep. 2022 Oct 4;4(11):526-532. doi: 10.1253/circrep.CR-22-0094.
6. Power JR, Alexandre J, Choudhary A, Ozbay B, Hayek SS, Asnani A, Tamura Y, Aras M, Cautela J, Thuny F, Gilstrap L, Arangalage D, Ewer S, Huang S, Deswal A, Palaskas NL, Finke D, Lehmann LH, Ederhy S, Moslehi J, Salem JE; International ICI-Myocarditis Registry. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis, Arch Cardiovasc Dis, 2022 May;115(5):315-330. doi: 10.1016/j.acvd.2022.03.003. Epub 2022 Apr 27
7. Suzuki Y, Kanekoa H, Tamura Y, Okada A, Michihata N, Jo T, Takeda N, Morita H, Fujiua K, Node K, Yasunaga H, Komuro I. Sex-SpecificDifferencesintheRiskof HeartFailurefollowingAnti-HER2 MonoclonalAntibodyTherapy, Oncology, 2023. doi: 10.1159/000530215